TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary adenocarcinoma of the stomach, meeting the following criteria:~  * Newly diagnosed disease amenable to curative resection~ * Stage IB-III (T2-4)~* Measurable or nonmeasurable disease~* Enlarged lymph nodes outside of radiation fields must have preoperative biopsies~  * No positive lymph nodes outside of radiation fields~* No distant metastasis~* No gastroesophageal junction tumors~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm³~* WBC ≥ 3,000/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal~* Albumin ≥ 3 g/dL~* Bilirubin normal~* No evidence of ischemic heart disease by EKG~* No coronary artery disease requiring active medical treatment~* No symptoms of angina~* No history of myocardial infarction~* No deep vein thrombosis within the past 12 months~* No pre-existing peripheral neuropathy~* No active pneumonia or inflammatory lung infiltrate~* No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for ≥ 5 years~* No clinically significant comorbid medical conditions that would prevent delivery of chemotherapy, radiotherapy, or the performance of surgery~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior and no concurrent sorivudine or brivudine~* No prior therapy for this malignancy, including chemotherapy, surgery, immunotherapy, or radiotherapy~* No prior coronary angioplasty or stenting~* No concurrent 2-dimensional or intensity-modulated radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy, Chemoradiation, Surgery (Type: EXPERIMENTAL): Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 18 years of age or older.~* Patients must have either biopsy proven or radiographically suspected non-small cell lung cancer.~* Patients must have disease in the chest that is felt to be surgically resectable.~* ECOG performance status of 0-2.~* Ability to understand and the willingness to sign an IRB-approved informed consent document~Exclusion Criteria:~* Patients younger than 18 years of age~* Women who are pregnant or breast feeding.~* Patients may not be receiving any other investigational agents for the treatment of nonsmall cell lung cancer.~* Patients may not be taking the following medications: high dose vitamin A supplement (multivitamin supplements prohibited only if vitamin A content is greater than 3,500 international units), bexarotene, alitretinoin, tretinoin, adapalene, isotretinoin, acitretin, doxycycline, minocycline, or demeclocycline,~* Uncontrolled intercurrent illness including, but not limited to, pancreatitis, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Hypervitaminosis A - toxic effects of ingesting too much vitamin A.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin A compound (Type: EXPERIMENTAL): Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.
- Therapeutic Conventional Surgery (Type: ACTIVE_COMPARATOR): Description Participants undergo surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane PharmacokInetics in ARDS

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Presence for ≤ 12 hours of all of the following conditions, within one week of a clinical insult or new or worsening respiratory symptoms :~a PaO2/FiO2 \< 200 mmHg with positive end-expiratory pressure (PEEP) ≥ 8 cmH2O (or, if arterial blood gas not available : SpO2/FiO2 ratio that is equivalent to a PaO2/FiO2 \< 200 mmHg with PEEP ≥8 cmH2O, and a confirmatory SpO2/FiO2 ratio between 1-6 hours after the initial SpO2/FiO2 ratio determination) b Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules c Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present~Exclusion Criteria:~* Lack of informed consent~* Continuous sedation with inhaled sevoflurane at enrollment~* Currently receiving ECMO therapy~* Chronic respiratory failure defined as PaCO2 \> 60 mmHg in the outpatient setting~* Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep-disordered breathing~* Body mass index \> 40 kg/m2~* Chronic liver disease defined as a Child-Pugh score of 12-15~* Expected duration of mechanical ventilation \< 48 hours~* Tidal volume of 6 mL/kg predicted body weight (PBW) below 200 mL~* Decision to withhold life-sustaining treatment; except in those patients committed to full support except cardiopulmonary resuscitation~* Moribund patient, i.e. not expected to survive 24 hours despite intensive care~* Burns \> 70% total body surface~* Previous hypersensitivity or anaphylactic reaction to sevoflurane~* Medical history of malignant hyperthermia~* Suspected or proven intracranial hypertension~* Know pregnancy - Pregnancy testing will be systematically performed to rule out pregnancy in female patients of reproductive age~* Enrollment in another interventional ARDS trial with direct impact on sedation and PEEP~* Endotracheal ventilation for greater than 120 hours (5 days)~* PaO2/FiO2 (if available) \> 200 mmHg after meeting inclusion criteria and before start of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nonfocal ARDS (Type: EXPERIMENTAL): ARDS patient with nonfocal lung imaging phenotype
- Focal ARDS (Type: EXPERIMENTAL): ARDS patient with focal lung imaging phenotype

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Goal-directed Fluid Resuscitation in Acute Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* acute pancreatitis diagnosed by at least 2 criteria~* adult patients at least 18 years of age~Exclusion Criteria:~* history of severe cardiovascular, respiratory, renal, hepatic or hematologic/immunologic disease~* concurrent metabolic or physiologic derangement requiring specific fluid management~* pregnancy~* patients transferred from acute care hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Goal-directed fluid resuscitation with lactated Ringer's solution
- 2 (Type: EXPERIMENTAL): Goal-directed fluid resuscitation with normal saline
- 3 (Type: NO_INTERVENTION): Standard fluid resuscitation with lactated Ringer's solution
- 4 (Type: NO_INTERVENTION): Standard fluid resuscitation with normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Odors to Insufflate Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Newborns from a single or multiple pregnancy~* Newborns hospitalized in the Lyon East or Saint-Etienne neonatology services, of both sexes, born before 33 weeks of amenorrhea and after at least 6 days of life, without respiratory disease beside premature birth.~* Newborns must present at least 3 bradycardia during 3 days, or presenting apneas at observation.~* Newborns will be randomized if they present at least 3 apnea episodes per 24 hour monitored by RECAN for 3 consecutive days prior to randomization.~* Written informed consents obtained from the newborns parents or legal representatives~Exclusion Criteria:~* Severe congenital malformation~* History of allergic reaction to smell stimulation (cough, sneeze, watery eyes, breathing pauses)~* No social insurance

- Gender: ALL
- Minimum Age: 6 Days
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S0 - S1 - S2 (Type: EXPERIMENTAL): S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
- S0 - S2 - S1 (Type: EXPERIMENTAL): S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
- S1 - S0 - S2 (Type: EXPERIMENTAL): S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
- S1 - S2 -S0 (Type: EXPERIMENTAL): S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
- S2 - S0 - S1 (Type: EXPERIMENTAL): S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
- S2 - S1 - S0 (Type: EXPERIMENTAL): S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DBS of Posterior Subthalamic Area (PSA) and Ventral Intermediate Nucleus (VIM) in Essential Tremor (ET)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a diagnosis of ET, refractory to pharmacotherapy referred for DBS consideration.~* Informed consent signed by the subject.~* DBS candidate per FDA guidelines.~* Primary language - English~* Physically and cognitively capable of completing evaluations and consent~* Medically cleared for surgery and anesthesia~* Negative pregnancy test prior to surgery for female subjects of child-bearing potential.~Exclusion Criteria:~* Any individuals with contraindication to bilateral DBS lead placement, history of dementia per DSM-V criteria, intracranial hemorrhage, or psychiatric illness.~* Conditions precluding MRI.~* History of supraspinal disease.~* Subjects with a history of seizure disorder.~* Subjects who have made a suicide attempt within the prior year,~* Subjects with any medical contraindications to undergoing DBS surgery (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery)~* Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator, neurostimulator and cochlear implant~* Subjects who are pregnant or nursing.~* Patient that is unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol.~* Any other reasons that, in the opinion of the investigator, the candidate is determined to be unsuitable for entry into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Subjects will receive VIM stimulation for two weeks, followed by VIM+PSA stimulation for two weeks, and finally PSA stimulation for two weeks.
- Group 2 (Type: EXPERIMENTAL): Subjects will receive VIM+PSA stimulation for two weeks, followed by PSA stimulation for two weeks, and finally VIM stimulation for two weeks.
- Group 3 (Type: EXPERIMENTAL): Subjects will receive PSA stimulation for two weeks, followed by VIM stimulation for two weeks, and finally VIM+PSA stimulation for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-Market Study Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* is at least 21 years of age and skeletally mature~* must have symptomatic degenerative disc disease at one level in the cervical spine, C3 to C7, demonstrated by herniated disc and/or spondylosis;~* must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment~* must score at least 15/50 (30%) on the Neck Disability Index~* is willing and able to follow the post-operative management program~* must understand and sign the informed consent document~Exclusion Criteria:~* symptomatic cervical DDD at more than one level~* axial neck pain as the primary diagnosis without evidence of neural compression~* neck or arm pain of unknown etiology~* any significant anatomical consideration which would make the anterior cervical approach excessively risky or impossible~* severe spondylosis at the target level~* prior surgery at the target level~* fused level adjacent to the target level~* osteoporosis, osteopenia, osteomalacia, Paget's disease or metabolic bone disease~* active infection or surgical site infection~* is using any medication known to interfere with bone/soft tissue healing~* diabetes mellitus requiring daily insulin management~* any terminal, systemic, or autoimmune disease~* medical conditions or mental incompetence which may interfere with study requirements~* BMI \>40 or a weight more than 100 lbs over ideal body weight~* chemical dependency problem that may interfere with study requirements~* current smokers~* history of any invasive malignancy unless treated and in remission for at least two years~* documented allergies to metal or plastic~* currently pregnant, or interested in becoming pregnant during the study follow-up

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NuNec Cervical Disc (Type: EXPERIMENTAL): Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Alcohol Dependence With Gabapentin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age more then 18 years~2. Meet the Diagnostic and Statistical Manual-Fourth Edition (DSM-V) criteria for current alcohol dependence~Exclusion Criteria:~1. Risk for significant withdrawal based on a Clinical Institute Withdrawal Assessment-Alcohol, Revised (CIWA-AR) score \>9~2. More than one month of abstinence~3. Dependence on substances other than alcohol~4. A urine drug screen positive for benzodiazepines or opiates~5. Clinically significant medical or psychiatric disorders treatment with medications that could affect study outcomes~6. Treatment mandated by a legal authority

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- gabapentin (Type: EXPERIMENTAL): Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
- Placebo (Type: PLACEBO_COMPARATOR): Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or over~* Definite Enterococcal endocarditis, as defined by modified Duke criteria~* Able to complete follow-up 3 and 6 weeks following completion of intravenous antibiotic therapy~Exclusion Criteria:~* Pregnancy or breast feeding~* Creatine phosphokinase levels over two times the upper limit of normal~* Renal insufficiency or dialysis requirement.~* Presence of chronic indwelling bloodstream catheters or foreign body devices suspected as primary or secondary sites of enterococcal infection unamenable to removal or replacement~* Inability to discontinue or abstain from use of a HMG CoA reductase inhibitor during the study period.~* Hypersensitivity to any of the study medications.~* Any condition that, in the investigator's opinion, may interfere with protocol compliance including, but not limited to, active substance abuse and/or dementia.~* Prosthetic valve endocarditis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daptomycin adjunctive group (Type: EXPERIMENTAL): Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
- standard of care (Type: NO_INTERVENTION): Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Colonoscopy for Lower Gastrointestinal (GI) Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who are admitted with rectal bleeding and one of the following high-risk features:~1. HR \> 100/min~2. Systolic blood pressure \<100 mmHg~3. Orthostasis -considered as increase in HR by\> 20/min on assuming erect position as well as by decrease by 20 mmHg in systolic blood pressure~4. Need for blood transfusion~5. Drop in hemoglobin \> 1.5 g/dl or in hematocrit of \> 6% in 6 hours~Exclusion Criteria:~1. Inability to give informed consent~2. Peritoneal signs~3. Severe co-morbidities that would preclude the use of colonoscopy in standard clinical practice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early colonoscopy (Type: EXPERIMENTAL): Colonoscopy performed within 12 hours of presentation
- Elective colonoscopy (Type: ACTIVE_COMPARATOR): Colonoscopy 36-60 hours after presentation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Biopsy-proven rectal adenocarcinoma of the rectum with clinically suspected or previously known stage I-IIIB (cT1-4, N0-2, M0) disease~* Anticipated or prior chemoradiation as part of an NOM treatment strategy~* Ability to understand and willingness to sign an IRB-approved written informed consent document~Exclusion Criteria:~* Prior surgical resection of rectal cancer (endoscopic or TME)~* Contraindication to MRI~* Comorbidities that would limit patient's ability to cooperate with a PET/MRI examination (e.g. dementia, inability to follow commands, claustrophobia, tremors, requirement for oxygen by nasal cannula, etc...).~* Implanted devices or materials that may interfere with MRI imaging or create significant artifact~* Pregnancy~* Contraindication to gadolinium contrast or FDG~* End-stage renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FDG PET/MRI (Type: EXPERIMENTAL): -Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 6 time-points at which it would normally be performed in their care for the period of time extending 30-36 months from the time of enrollment (depending on enrollment point). In the surveillance period, when patients typically undergo pelvic MRI every 3 months, the FDG-PET/MRI will be done in lieu of the standard pelvic MRI on an approximately every-other-scan basis. In other words, the FDG-PET/MRI will occur roughly once every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility